Lipolysis SAXENDA

Saxenda is a medication used for weight management in adults who have obesity or overweight with at least one weight-related condition. Here are some key points about Saxenda:
Purpose: Saxenda is prescribed to help individuals lose weight and maintain a healthier lifestyle.

Active Ingredient: The active ingredient in Saxenda is liraglutide, which works by mimicking a hormone called GLP-1 that regulates appetite and calorie intake.

Administration: Saxenda is usually injected under the skin (subcutaneously) once a day, either in the abdomen, thigh, or upper arm. The dosage may vary depending on individual needs and tolerability.

Weight Loss Benefits: Patients using Saxenda may experience significant weight loss when combined with a reduced-calorie diet and increased physical activity.

Effectiveness: Saxenda has shown effectiveness in aiding weight loss when used as directed alongside lifestyle modifications. HOW DOES SAXENDA WORK?
Weight loss when using Saxenda® is associated with the regulation of appetite and the amount of food consumed. Appetite was assessed before and within 5 hours after the standardized breakfast; unrestricted food intake was assessed during the subsequent meal. Compared with placebo, Saxenda® increased the feeling of fullness and fullness of the stomach after a meal and reduced the feeling of hunger and the estimated amount of expected food intake, as well as reduced unrestricted food intake. No treatment-related increase in 24-hour energy expenditure was noted when assessed with a respiratory chamber.

The efficacy and safety of the use of Saxenda® for long-term body weight correction in combination with a low-calorie diet and increased physical activity was studied in 4 randomized, double-blind, placebo-controlled, phase 3 SCALE studies, which included a total of 5358 adult patients.

Treatment:

SAXENDA INDICATIONS
Saxenda® is indicated as an addition to a low-calorie diet and increased physical activity for long-term use in order to correct body weight in adult patients with BMI:

• ≥ 30 kg/m2 (obese) or

• ≥ 27 kg/m2 to < 30 kg/m2 (overweight) with at least one overweight comorbidity such as prediabetes, type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea.

How to Use

https://www.saxenda.com/about-saxenda/how-to-use-the-pen.html

https://www.novo-pi.com/saxenda.pdf#page=11

Indicators:

Stomach Area (Abdomen);
Upper Leg (Thigh);
Upper arm